Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target
$IINN
Medical/Dental Instruments
Health Care
Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $9.00 → $10.00 | Buy | Aegis Capital |
| 8/26/2021 | $9.00 | Buy | Aegis Capital |
RA'ANANA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that the Japan Patent Office has granted Patent No. 7777598. This patent covers the Company's novel Convertible Dual Lumen Cannula device and method of use, securing exclusive rights in one of the world's most advanced medical device markets. The patent grants Inspira exclusive commercial rights in the patented Dual Lumen Cannula technology in Japan through 2041. This milestone complements the Company's existing U.S. Patent (granted in 2023), further e
RA'ANANA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of its core blood laboratory capabilities, marking a substantial step in the Company's evolution into a broader cutting edge technologies, positioning it for accelerated future growth. The strategic expansion includes transitioning to a substantially larger, state-of-the-art laboratory facility, while planning to increase recruitment of specialized personnel, upgrading advanced research instrumentation, and expanding its operation
RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the completion of the clinical study for its HYLA, non-invasive blood sensor, toward regulatory submission and future commercialization. Based on the clinical trial results and ongoing lab tests, showing between 95% to 99% accuracy across measured parameters, Inspira is soon entering the final validation and verification stage ahead of planned regulatory submission. Inspira is leveraging its proprietary non-invasive platform and integrating advanced
Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously
Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
F-3/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als
Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn
RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio
Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an
Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today. On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)